Clinical Trial Update: Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing the combination of cetuximab with stereotactic radiation therapy for patients with recurrent head and neck cancer not amenable …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Cetuximab (cetuximab)

Snippet

Sponsor: Centre Oscar Lambret | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED